UROXATRAL
Pronunciation: al-FYOO-zoe-sin (yoo-ROX-a-tral)

What it isAlpha-1 antagonist with functional uroselectivity; benign prostatic hyperplasia.
Why this oneLess ejaculatory dysfunction than tamsulosin, and no titration is needed.
What limits itOrthostatic hypotension and QT prolongation. CYP3A4-dependent, so strong inhibitors are contraindicated.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Benign prostatic hyperplasia | Men | 10 mg QD with food (same meal each day) | 10 mg QD |
Renal Use with caution in severe impairment (CrCl <30 mL/min); no specific dose adjustment
Hepatic Contraindicated in moderate-severe impairment (Child-Pugh B/C); use caution in mild (not studied)
Available strengths
Pregnancy Not indicated for use in women.
Lactation Not indicated for use in women.
| Strength | #/mo | generic $/mo | CostPlus | |
|---|---|---|---|---|
| 10 mg | ER tab | 30 qd | $3.15 | offered |
Generic entry2011
NO BOXED WARNINGS
Principal riskOrthostatic hypotension; QT prolongation
Legacy pregnancy categoryC
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.